MCID: PRP016
MIFTS: 39

Paraplegia malady

Categories: Rare diseases, Neuronal diseases

Aliases & Classifications for Paraplegia

About this section

Aliases & Descriptions for Paraplegia:

Name: Paraplegia 10 45 12 36 65
Severe or Complete Loss of Motor Function in the Lower Extremities and Lower Portions of the Trunk 45
 
Paraplegia, Lower 10

Classifications:



External Ids:

Disease Ontology10 DOID:607
ICD1027 G82.2, G82.20
ICD9CM29 344.1
SNOMED-CT59 155031004, 60389000
MeSH36 D010264
NCIt42 C50687
UMLS65 C0030486

Summaries for Paraplegia

About this section
Wikipedia:68 Paraplegia is an impairment in motor or sensory function of the lower extremities. The word comes from... more...

MalaCards based summary: Paraplegia, also known as severe or complete loss of motor function in the lower extremities and lower portions of the trunk, is related to spastic paraplegia 4 and spastic paraplegia 1. An important gene associated with Paraplegia is SPG7 (SPG7, Paraplegin Matrix AAA Peptidase Subunit), and among its related pathways is Endocytosis. Affiliated tissues include spinal cord, bone and breast, and related mouse phenotypes are nervous system and behavior/neurological.

Related Diseases for Paraplegia

About this section

Diseases related to Paraplegia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 836)
idRelated DiseaseScoreTop Affiliating Genes
1spastic paraplegia 434.3ATL1, SPAST
2spastic paraplegia 133.1FA2H, SPAST, SPG11
3holoprosencephaly27.7ATL1, CYP7B1, HSPD1, KIAA0196, KIF5A, L1CAM
4hereditary spastic paraplegia12.6
5spastic paraplegia 712.5
6spastic paraplegia 1112.5
7spastic paraplegia 1512.5
8spastic paraplegia 212.5
9spastic paraplegia 812.5
10spastic paraplegia 3112.4
11spastic paraplegia 39, autosomal recessive12.4
12spastic paraplegia 45, autosomal recessive12.4
13spastic paraplegia 6, autosomal dominant12.4
14spastic paraplegia 3a, autosomal dominant12.4
15spastic paraplegia 49, autosomal recessive12.4
16spastic paraplegia 54, autosomal recessive12.4
17spastic paraplegia 30, autosomal recessive12.4
18spastic paraplegia 56, autosomal recessive12.4
19spastic paraplegia 46, autosomal recessive12.4
20spastic paraplegia 28, autosomal recessive12.4
21spastic paraplegia 35, autosomal recessive12.4
22spastic paraplegia 43, autosomal recessive12.4
23spastic paraplegia 6312.4
24spastic paraplegia 57, autosomal recessive12.4
25spastic paraplegia 42, autosomal dominant12.4
26spastic paraplegia 48, autosomal recessive12.4
27spastic paraplegia 53, autosomal recessive12.4
28spastic paraplegia 55, autosomal recessive12.4
29spastic paraplegia 1712.4
30spastic paraplegia 5a, autosomal recessive12.4
31spastic paraplegia 10, autosomal dominant12.4
32spastic paraplegia 18, autosomal recessive12.4
33spastic paraplegia, optic atrophy, and neuropathy12.4
34spastic paraplegia 26, autosomal recessive12.4
35spastic paraplegia 61, autosomal recessive12.4
36spastic paraplegia 12, autosomal dominant12.4
37spastic paraplegia 13, autosomal dominant12.4
38spastic paraplegia 64, autosomal recessive12.4
39spastic paraplegia 72, autosomal recessive12.3
40spastic paraplegia 73, autosomal dominant12.3
41spastic paraplegia 11, autosomal recessive12.3
42spastic paraplegia 3a12.3
43silver spastic paraplegia syndrome12.3
44spastic paraplegia 2312.3
45spastic paraplegia 4, autosomal dominant12.3
46spastic paraplegia 2, x-linked12.3
47spastic paraplegia 15, autosomal recessive12.3
48spastic paraplegia 44, autosomal recessive12.3
49spastic paraplegia 31, autosomal dominant12.3
50spastic paraplegia 33, autosomal dominant12.3

Graphical network of the top 20 diseases related to Paraplegia:



Diseases related to paraplegia

Symptoms for Paraplegia

About this section

Drugs & Therapeutics for Paraplegia

About this section

Drugs for Paraplegia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 93)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
AcetazolamideapprovedPhase 46759-66-51986
Synonyms:
1424-27-7 (mono-hydrochloride salt)
1yda
1ydb
1ydd
1zsb
2-acetylamino-1,3,4-Thiadiazole-5-sulfonamide
2h4n
3czv
4-Diamox
5-ACETAMIDO-1,3,4-thiadiazole-2-sulfonamide
5-acetylamino-1,3,4-Thiadiazole-2-sulfonamide
5661-25-6
59-66-5
8017-69-4
A 6011
A6011_SIAL
A6011_SIGMA
AB00051906
AC-12779
AC1L1CO5
AI3-52458
AKOS000715163
Acetadiazol
Acetamidothiadiazolesulfonamide
Acetamox
Acetazolam
Acetazolamid
Acetazolamida
Acetazolamida [INN-Spanish]
Acetazolamide
Acetazolamide (AAZ)
Acetazolamide (JP15/USP/INN)
Acetazolamide Apotex Brand
Acetazolamide Chiesi Brand
Acetazolamide Dioptic Brand
Acetazolamide Grin Brand
Acetazolamide ICN Brand
Acetazolamide Jumer Brand
Acetazolamide Llorens Brand
Acetazolamide Medphano Brand
Acetazolamide Novopharm Brand
Acetazolamide Orion Brand
Acetazolamide Sodium
Acetazolamide Sodium, (Sterile)
Acetazolamide Wassermann Brand
Acetazolamide [INN:BAN:JAN]
Acetazolamide, Monosodium Salt
Acetazolamidum
Acetazolamidum [INN-Latin]
Acetazolamine
Acetazoleamide
Acetozalamide
Acétazolamide
Ak Zol
Ak-Zol
AkZol
Apo Acetazolamide
Apo-Acetazolamide
ApoAcetazolamide
Apotex Brand of Acetazolamide
Atenezol
Avva
BAS 01585728
BIDD:GT0643
BPBio1_000007
BSPBio_000005
BSPBio_001788
C06805
C4H6N4O3S2
CAS-59-66-5
CCRIS 5811
CHEBI:27690
CHEMBL20
CID1986
CPD0-1626
CPD000058394
Carbonic Anhydrase Inhibitor 6063
Carbonic Anhydrase Inhibitor No. 6063
Carbonic anhydrase inhibitor 6063
Chiesi Brand of Acetazolamide
Ciba Vision Brand of Acetazolamide
Cidamex
D000086
D00218
DB00819
Dazamide
Defiltran
Dehydratin
Diacarb
Diakarb
Diamox
Diamox (TN)
Diamox Sequels
Didoc
 
Diluran
Dioptic Brand of Acetazolamide
Diuramid
Diuramide
Diureticum-Holzinger
Diureticum-holzinger
Diuriwas
Diutazol
DivK1c_000017
Donmox
Duiramid
EINECS 200-440-5
EU-0100039
Edemox
Eumicton
Fonurit
Glauconox
Glaumox
Glaupax
Glupax
Grin Brand of Acetazolamide
HMS1568A07
HMS1920A05
HMS2091G05
HMS500A19
HSDB 3002
Huma Zolamide
Huma-Zolamide
HumaZolamide
I09-0425
ICN Brand of Acetazolamide
IDI1_000017
Jumer Brand of Acetazolamide
KBio1_000017
KBio2_000358
KBio2_002926
KBio2_005494
KBio3_001288
KBioGR_000558
KBioSS_000358
LS-10227
Llorens Brand of Acetazolamide
Lopac-A-6011
Lopac0_000039
MLS000028435
MLS001148438
Medphano Brand of Acetazolamide
MolPort-001-783-578
Monosodium Salt Acetazolamide
N-[5-(Aminosulfonyl)-1,3,4-thiadiazol-2-yl]acetamide
N-[5-(Aminosulfonyl)-1,3,5-thiadiazol-2-yl]acetamide
NCGC00015074-01
NCGC00015074-02
NCGC00015074-03
NCGC00015074-06
NCGC00015074-11
NCGC00023455-03
NCGC00023455-04
NCGC00023455-05
NCGC00023455-06
NCGC00023455-07
NINDS_000017
NSC 145177
NSC145177
Natrionex
Nephramid
Nephramide
Novopharm Brand of Acetazolamide
Orion Brand of Acetazolamide
Phonurit
Prestwick0_000003
Prestwick1_000003
Prestwick2_000003
Prestwick3_000003
Prestwick_4
SAM002554883
SBB056640
SK-acetazolamide
SMR000058394
SPBio_000004
SPBio_001926
SPECTRUM1500102
Sk-Acetazolamide
Spectrum2_000082
Spectrum3_000284
Spectrum4_000139
Spectrum5_000738
Spectrum_000018
Storz Brand of Acetazolamide Preparation
Storzolamide
UNII-O3FX965V0I
Vetamox
WLN: T5NN DSJ CSZW EMV1
Wassermann Brand of Acetazolamide
Wyeth Brand of Acetazolamide Preparation
acetazolamide
2diureticsPhase 41194
3Natriuretic AgentsPhase 41403
4Carbonic Anhydrase InhibitorsPhase 4153
5AnticonvulsantsPhase 42249
6
Minocyclineapproved, investigationalPhase 2, Phase 317310118-90-85281021
Synonyms:
(2Z,4S,4aS,5aR,12aS)-2-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE
(4S,4AS,5ar,12as)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
10118-90-8
13614-98-7 (mono-hydrochloride)
4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
4708-96-7
7-Dimethylamino-6-demethyl-6-deoxytetracycline
AC1NQXWM
Arestin
BRN 3077644
Bio-0062
Borymycin
C07225
C23H27N3O7
CHEBI:50694
CHEBI:529981
CHEMBL1434
CHEMBL259172
CID5281021
CL 59806
CRL-1605 & Minocycline
D05045
Dynacin
HMS2090D03
HSDB 3130
LMPK07000002
 
LS-93850
Lactoferrin B & Minocycline
Lactoferrin H & Minocycline
MINO
MIY
Minociclina
Minociclina [INN-Spanish]
Minociclinum
Minocin
Minocin (Hydrochloride)
Minocline
Minocyclin
Minocycline
Minocycline (USAN/INN)
Minocycline Hydrochloride
Minocycline Monohydrochloride
Minocycline [USAN:BAN:INN]
Minocyclinum
Minocyclinum [INN-Latin]
NCGC00178854-01
NSC 141993
NSC141993
Solodyn
UNII-FYY3R43WGO
Vectrin (Hydrochloride)
Ximino
minociclinum
minocycline
nchembio.559-comp1
7
AcetylcholineexperimentalPhase 2, Phase 368951-84-3187
Synonyms:
ACh
Acetyl choline ion
Acetylcholine Chloride
Acetylcholine cation
 
Acetylcholinium: acetyl-Choline
Choline acetate
Choline acetate (ester)
Miochol E
O-Acetylcholine
acetylcholine chloride
8Fibrin Tissue AdhesivePhase 2, Phase 3, Phase 1138
9Neurotransmitter AgentsPhase 2, Phase 3, Phase 114795
10Botulinum ToxinsPhase 2, Phase 3616
11CortivazolPhase 32
12Anti-Inflammatory AgentsPhase 3, Phase 28478
13Cholinergic AgentsPhase 2, Phase 33243
14Anti-Infective AgentsPhase 2, Phase 317220
15Anti-Bacterial AgentsPhase 2, Phase 39140
16
LevodopaapprovedPhase 1, Phase 236359-92-76047
Synonyms:
(-)-(3,4-Dihydroxyphenyl)alanine
(-)-3-(3,4-Dihydroxyphenyl)-L-alanine
(-)-3-(3,4-dihydroxyphenyl)-L-alanine
(-)-Dopa
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid
(−)-3-(3,4-dihydroxyphenyl)-L-alanine
(−)-dopa
.Beta.-(3, 4-Dihydroxyphenyl)alanine
.Beta.-(3,4-Dihydroxyphenyl)-L-alanine
1E83F927-C221-46AA-B90A-81B33C5F3868
2-Amino-3-(3,4-dihydroxyphenyl)propanoic acid
23734-74-9
25525-15-9
3, 4-Dihydroxy-L-phenylalanine
3, 4-Dihydroxyphenylalanine
3,4-DIHYDROXYPHENYLALANINE
3,4-Dihydroxy-L-phenylalanine
3,4-Dihydroxyphenyl-L-alanine
3,4-Dihydroxyphenylalanine
3,4-Dihydroxyphenylalanine (VAN)
3,4-dihydroxy-L-phenylalanine
3,4-dihydroxyphenylalanine
3-(3,4-Dihydroxypheny
3-(3,4-Dihydroxyphenyl)-L-alanine
3-Hydroxy-L-tyrosine
34241-25-3
37830_FLUKA
587-45-1
59-92-7
72572-99-7
72573-00-3
88250-23-1
90638-38-3
AC-11686
AC1L1LOR
AC1Q4U7F
BIDD:GT0158
BPBio1_000059
BSPBio_000053
BSPBio_002354
Bendopa
Bio-0575
Biodopa
Brocadopa
C00355
C9H11NO4
CAS-59-92-7
CCRIS 3766
CHEBI:15765
CHEMBL1009
CID6047
Cerepap
Cidandopa
D 9628
D00059
D0600
D9628
D9628_SIGMA
DAH
DB01235
DOPA
Deadopa
Dihydroxy-L-phenylalanine
Dihydroxyphenylalanine
DivK1c_000452
Dopa
Dopaflex
Dopaidan
Dopal
Dopal-Fher
Dopal-fher
Dopalina
Dopar
Dopar (TN)
Doparkine
Doparl
Dopasol
Dopaston
Dopaston SE
Dopastone
Dopastral
Dopicar
Doprin
EINECS 200-445-2
EU-0100454
Eldopal
Eldopar
Eldopatec
Eurodopa
HMS1568C15
HMS1922J14
HMS2090O08
HMS2093N04
HMS501G14
HSDB 3348
Helfo DOPA
 
Helfo-Dopa
Helfo-dopa
IDI1_000452
IV Levodopa
InChI=1/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14
Insulamina
KBio1_000452
KBio2_000934
KBio2_003502
KBio2_006070
KBioGR_001177
KBioSS_000934
L Dopa
L(-)-Dopa
L-(-)-Dopa
L-(3, 4-Dihydroxyphenyl)-.alpha.-alani
L-(3, 4-Dihydroxyphenyl)alanine
L-(o-Dihydroxyphenyl)alanine
L-.Beta.-(3,4-Dihydroxyphenyl)alanine
L-3,4-Dihydroxyphenylalanine
L-3,4-dihydroxyphenylalanine
L-3-(3,4-Dihydroxyphenyl)-Alanine
L-3-(3,4-Dihydroxyphenyl)alanine
L-3-Hydroxytyrosine
L-4-5-Dihydroxyphenylalanine
L-DOPA
L-DOPA, Parcopa, Atamet, Stalevo, Madopar, Prolopa, Dopar, 3,4-Dihydroxyphenylalanine, Levodopa
L-Dihydroxyphenylalanine
L-Dopa
L-O-Dihydroxyphenylalanine
L-b-(3,4-Dihydroxyphenyl)-a-alanine
L-beta-(3,4-Dihydroxyphenyl)-alpha-alanine
L-beta-(3,4-Dihydroxyphenyl)alanine
L-o-Hydroxytyrosine
LS-255
Laradopa
Larodopa
Ledopa
Levedopa
Levodopa
Levodopa (JP15/USP)
Levodopa (JP15/USP/INN)
Levodopa [USAN:INN:BAN:JAN]
Levodopum
Levodopum [INN-Latin]
Levopa
Lopac-D-9628
Lopac0_000454
MLS000028514
Maipedopa
MolPort-000-856-937
NCGC00015384-01
NCGC00016270-01
NCGC00016270-06
NCGC00093869-04
NINDS_000452
NSC 118381
NSC118381
PDSP1_001541
PDSP2_001525
Parda
Pardopa
Prestwick0_000017
Prestwick1_000017
Prestwick2_000017
Prestwick3_000017
Prestwick_185
Prodopa
Ro 4-6316
S1726_Selleck
SDCCGMLS-0066924.P001
SMR000058312
SPBio_000391
SPBio_001974
SPECTRUM2300205
Sobiodopa
Spectrum2_000496
Spectrum4_000539
Spectrum5_001899
Spectrum_000454
Syndopa
UNII-46627O600J
Veldopa
Weldopa
b-(3,4-Dihydroxyphenyl)-L-alanine
b-(3,4-Dihydroxyphenyl)-a-L-alanine
b-(3,4-Dihydroxyphenyl)alanine
beta-(3,4-Dihydroxyphenyl)-L-alanine
beta-(3,4-Dihydroxyphenyl)-alpha-L-alanine
beta-(3,4-Dihydroxyphenyl)-alpha-alanine
beta-(3,4-Dihydroxyphenyl)alanine
bmse000322
component of Sinemet
l)-L-alanine
nchembio.2007.55-comp26
nchembio.89-comp9
ne
β-(3,4-dihydroxyphenyl)alanine
17
CarbidopaapprovedPhase 1, Phase 215928860-95-934359, 38101
Synonyms:
(-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid
(-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate
(2S)-3-(3,4-Dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid hydrate
(2S)-3-(3,4-Dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid monohydrate
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropanoic acid
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid hydrate
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid monohydrate
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid--water (1/1)
(AlphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate
(S)-(-)-Carbidopa hydrate
(S)-(-)-carbidopa
(S)-(-)-carbidopa hydrate
(S)-(−)-carbidopa hydrate
(S)-alpha--Hydrazino-3,4-dihydroxy-alpha--methyl-benzenepropanoic acid monohydrate
(S)-carbidopa
(S)-carbidopa hydrate
(alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid
(alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate
27925-91-3
28860-95-9
31823-41-3
38821-49-7
AC-1676
AC1L1RFR
AC1L1Z32
AC1Q5QGW
Atamet
BB_SC-5095
Benzenepropanoic acid, alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate, (S)
C-126
C-DOPA
C126_SIGMA
C1335_SIGMA
CCRIS 5093
CHEBI:3395
CHEBI:39585
CHEMBL1200748
CHEMBL1201236
CID34359
CID38101
CPD-11550
Carbidopa
Carbidopa (anhydrous)
Carbidopa Anhydrous
Carbidopa Monohydrate
Carbidopa [USAN:INN:BAN]
Carbidopa anhydrous
Carbidopa hydrate
Carbidopa monohydrate
Carbidopa, (S)-Isomer
 
Carbidopa, Entacapone, & Levodopa
Carbidopa-1-wasser
Carbidopum
Carbidopum [INN-Latin]
Carbidopum monohydricum
DB00190
EINECS 249-271-9
EU-0100382
HMS2089B12
Hadrazino-alpha-methyldopa
Hydrocinnamic acid, (-)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate
KINSON, 3-(3,4-DIHYDROXY-PHENYL)-2-HYDRAZINO-2-METHYL-PROPIONIC ACID
L-3-(3,4-Dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid
L-alpha-(3,4-Dihydroxybenzyl)-alpha-hydrazinopropionic acid monohydrate
L-alpha-(3,4-dihydroxybenzyl)-alpha-hydrazinopropionic acid monohydrate
L-alpha-Methyl-alpha-hydrazino-beta-(3,4-dihydroxyphenylpropionic acid
L-alpha-Methyl-beta-(3,4-dihydroxyphenyl)-alpha-hydrazinopropionic acid
L-alpha-Methyldopahydrazine
LS-77199
Lodosin
Lodosyn
Lodosyn, Carbidopa
Lopac0_000382
MK 486
MK-485
MK-486
MLS000069628
MLS002207014
Methyldopahydrazine
MolPort-003-940-629
MolPort-005-934-181
N-Aminomethyldopa
NCGC00024596-01
NCGC00024596-03
NCGC00024596-05
NCGC00024596-06
S(-)-CARBIDOPA
S(-)-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate
S-(-)-Carbidopa
S-(-)-alpha-Hydrazino-3,4-dihydroxy-2-methylbenzenepropanoic acid
S1891_Selleck
SMP1_000057
SMR000058235
ST055523
Stalevo
Tocris-0455
UNII-KR87B45RGH
UNII-MNX7R8C5VO
alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid
alpha-Methyldopahydrazine
carbidopa
carbidopa hydrate
carbidopum monohydricum
18
DopamineapprovedPhase 1, Phase 2308462-31-7, 51-61-6681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine Hcl
Dopamine Hydrochloride
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
 
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
19
Buspironeapproved, investigationalPhase 1, Phase 24336505-84-72477
Synonyms:
36505-84-7
8-(4-(4-(2-Pyrimidinyl)-1-piperizinyl)butyl)-8-azaspiro(4,5)decane-7,9-dione
8-[4-(4-Pyrimidin-2-yl-piperazin-1-yl)-butyl]-8-aza-spiro[4.5]decane-7,9-dione
8-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione
8-{4-[4-(pyrimidin-2-yl)piperazin-1-yl]butyl}-8-azaspiro[4.5]decane-7,9-dione
AB00053432
AC1L1DRN
AKOS002313325
Ansial
Ansiced
Anxiron
Axoren
BAS 00928841
BIDD:GT0519
BPBio1_000547
BPBio1_001403
BRD-K93461745-001-01-5
BRD-K93461745-003-03-7
BRN 0964904
BSPBio_000497
Bespar
Biomol-NT_000108
Buspiron
Buspirona
Buspirona [INN-Spanish]
Buspirone
Buspirone (INN)
Buspirone Hydrochloride
Buspirone [INN:BAN]
Buspirone-MDTS
Buspironum
Buspironum [INN-Latin]
Buspisal
C06861
C13H21NO2.C9H14N4
CAS-33386-08-2
CHEBI:3223
CHEMBL49
 
CID2477
D07593
DB00490
DivK1c_000921
EINECS 253-072-2
Gen-Buspirone
Gen-Buspirone (TN)
HMS2090K19
IDI1_000921
KBio1_000921
KBio2_002236
KBio2_004804
KBio2_007372
KBioSS_002236
L001110
LS-22723
Lopac-B-7148
Lopac0_000223
MJ-9022-1
MolPort-002-539-709
N-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-1-cyclopentanediacetamide
NCGC00015162-01
NCGC00015162-06
NCGC00016820-01
NCGC00024905-01
NCGC00024905-02
NCGC00024905-03
NINDS_000921
Prestwick0_000369
Prestwick1_000369
Prestwick2_000369
Prestwick3_000369
SPBio_002418
STK086268
STOCK1S-11244
Spectrum_001756
Tocris-0962
UNII-TK65WKS8HL
buspirone
20
chenodeoxycholic acidapprovedPhase 225474-25-910133
Synonyms:
(+)-chenodeoxycholate
(+)-chenodeoxycholic acid
(3a,5b,7a)-3,7-dihydroxy-cholan-24-oate
(3a,5b,7a)-3,7-dihydroxy-cholan-24-oic acid
3a,7a-Dihydroxy-5b,14a,17b-cholanate
3a,7a-Dihydroxy-5b,14a,17b-cholanic acid
3a,7a-Dihydroxy-5b-cholan-24-oate
3a,7a-Dihydroxy-5b-cholan-24-oic acid
3a,7a-Dihydroxy-5b-cholanate
3a,7a-Dihydroxy-5b-cholanic acid
3alpha,7alpha-Dihydroxy-5beta-cholanic acid
7a-Hydroxy-desoxycholsaeure
 
7alpha-Hydroxylithocholic acid
Anthropodeoxycholic acid
Anthropodesoxycholic acid
CDCA
Chenic acid
Chenix
Chenocholic acid
Chenodal
Chenodeoxycholate
Chenodeoxycholic acid
Chenodesoxycholic acid
Chenodesoxycholsaeure
Chenodiol
Gallodesoxycholic acid
21
Resveratrolexperimental, investigationalPhase 2105501-36-0, 955365-80-724856436, 445154
Synonyms:
(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol
(E)-5-(p-Hydroxystyryl)resorcinol
(E)-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol
(E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol
(E)-resveratrol
 
3,4',5-Stilbenetriol
3,4',5-Trihydroxystilbene
3,4',5-trihydroxy-stilbene
MK-1775
trans-3,4',5 - Trihydroxystilbene
trans-3,4',5-trihydroxystilbene
trans-Resveratrol
22Tranquilizing AgentsPhase 1, Phase 23597
23Anti-Anxiety AgentsPhase 1, Phase 21529
24AnalgesicsPhase 29358
25Serotonin AgentsPhase 1, Phase 22668
26
SerotoninPhase 1, Phase 2314750-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
27Central Nervous System DepressantsPhase 1, Phase 210016
28Carbidopa, levodopa drug combinationPhase 1, Phase 2104
29Peripheral Nervous System AgentsPhase 218510
30Dopamine AgentsPhase 1, Phase 23084
31Antiparkinson AgentsPhase 1, Phase 21312
32Psychotropic DrugsPhase 1, Phase 25501
33Pharmaceutical SolutionsPhase 27004
34HemagglutininsPhase 2111
35AbobotulinumtoxinAPhase 2588
36OnabotulinumtoxinAPhase 2588
37Botulinum Toxins, Type APhase 2588
38Neuromuscular AgentsPhase 2922
39IncobotulinumtoxinAPhase 2599
40Gastrointestinal AgentsPhase 26401
41CatharticsPhase 2344
42Protective AgentsPhase 25651
43Platelet Aggregation InhibitorsPhase 21935
44LaxativesPhase 2344
45Anti-Inflammatory Agents, Non-SteroidalPhase 23549
46Atorvastatin CalciumPhase 2714134523-03-8
47Antineoplastic Agents, PhytogenicPhase 24294
48Analgesics, Non-NarcoticPhase 25184
49Antirheumatic AgentsPhase 28496
50AntioxidantsPhase 22442

Interventional clinical trials:

(show top 50)    (show all 82)
idNameStatusNCT IDPhase
1Brain Function and White Matter Changes in Congenital, Acute and Chronic Spinal Cord LesionsCompletedNCT01208584Phase 4
2Effectiveness of Acetazolamide in Reducing Paralysis of the Leg in Patients Undergoing Aortic Aneurysm Surgery SurgeryRecruitingNCT01889498Phase 4
3Effect of Heat Exposure on Cognition in Persons With TetraplegiaRecruitingNCT02488824Phase 4
4Comparison of a Cortivazol (ALTIM®) Infiltration of Posterior Epidural Space at L3-L4 Stage Versus an Epidural Infiltration of Cortivazol (ALTIM®) on Contact With Disco Radicular Conflict in Discal SciaticaRecruitingNCT02151045Phase 3
5Retraining Walking After Spinal Cord InjuryActive, not recruitingNCT00059553Phase 2, Phase 3
6Effects of Botulinum Toxin Injections in Patients With Hereditary Spastic ParaplegiaNot yet recruitingNCT02604186Phase 2, Phase 3
7Prevention of Imminent Paralysis Following Spinal Cord Trauma or Ischemia by Minocycline: A Multi-center Study in Israel With IDF Primary Care InvolvementNot yet recruitingNCT01813240Phase 2, Phase 3
8Study of the Impact of the Use of a Corset on the Respiratory Function of Patients With Spinal Cord InjuryWithdrawnNCT01569360Phase 3
9Cethrin in Acute Cervical Spinal Cord InjuryWithdrawnNCT02053883Phase 2, Phase 3
10Study to Assess Safety, Tolerability and MTD of a Central Pattern Generator-activating Tritherapy (SPINALON) in Patients With Chronic Spinal Cord InjuryCompletedNCT01484184Phase 1, Phase 2
11A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cervical Spinal Cord InjuriesCompletedNCT00500812Phase 1, Phase 2
12Spinal Cord Injury Leg RehabilitationRecruitingNCT01498991Phase 1, Phase 2
13Treatment With Xeomin Versus Botox in Children With Spastic Equine and Equinovarus Foot Deformation in Pediatric Cerebral PalsyRecruitingNCT02188277Phase 2
14Feasibility of Telephone Counseling to Increase Physical Fitness in SCIRecruitingNCT02225028Phase 2
15Therapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5Active, not recruitingNCT02314208Phase 2
16Neural Stem Cell Transplantation in Traumatic Spinal Cord InjuryActive, not recruitingNCT02326662Phase 1, Phase 2
17Autologous Mesenchymal Stem Cells Transplantation in Thoracolumbar Chronic and Complete Spinal Cord Injury Spinal Cord InjuryNot yet recruitingNCT02574585Phase 2
18The Effects of Passive Gait Training in Complete Motor Spinal Cord Injury (SCI)Not yet recruitingNCT01349478Phase 1, Phase 2
19Autologous Incubated Macrophages for Patients With Complete Spinal Cord InjuriesSuspendedNCT00073853Phase 2
20Pressure Ulcer Formation Prevention in Paraplegics Using Computer and Sensory Substitution Via the Tongue.TerminatedNCT00429013Phase 2
21Orthostatic Tolerance During FES (Functional Electrical Stimulation)-Walking in ParaplegiaCompletedNCT00108043Phase 1
22Use of Interactive Gaming for Enhanced Function After Spinal Cord InjuryCompletedNCT01537978Phase 1
23Safety Study of Local Administration of Autologous Bone Marrow Stromal Cells in Chronic ParaplegiaCompletedNCT01909154Phase 1
24The ReWalk Exoskeletal Walking System for Persons With ParaplegiaRecruitingNCT01454570Phase 1
25SPATAX: Clinical and Genetic Analysis of Cerebellar Ataxias and Spastic ParaplegiasRecruitingNCT00140829Phase 1
26A Neuroprosthesis for Seated Posture and BalanceRecruitingNCT01474148Phase 1
27The Safety of ahSC in Chronic SCI With RehabilitationRecruitingNCT02354625Phase 1
28Safety of Autologous Human Schwann Cells (ahSC) in Subjects With Subacute SCIActive, not recruitingNCT01739023Phase 1
29Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar DegenerationsActive, not recruitingNCT00136630Phase 1
30Improving Ambulatory Community Access After ParalysisActive, not recruitingNCT01570816Phase 1
31Cohorts and Collections: Clinical and Genetic Study of Parkinson's Disease and EpilepsiesTerminatedNCT00142363Phase 1
32Nuclear Magnetic Spectroscopy Imaging to Evaluate Primary Lateral Sclerosis, Hereditary Spastic Paraplegia and Amyotrophic Lateral SclerosisCompletedNCT00023075
33Efficacy of Nebido on Bone Mineral Density (BMD) in Hypogonadal Paraplegic Patients With Confirmed OsteoporosisCompletedNCT00838838
34Effects of Exercise in People With ParaplegiaCompletedNCT01203150
35A Study Testing Safety and Tolerance of the ReWalk Exoskeleton SuitCompletedNCT00627107
36Exercise to Reduce Obesity in Spinal Cord InjuryCompletedNCT00270855
37Robotically Assisted Treadmill Training in Spinal Cord Injury (SCI)CompletedNCT00385918
38Medico-economical Impact of the Brindley Neurosurgical Technique in FranceCompletedNCT00221767
39Therapeutic Potential of Myofascial Structural Integration in Children With Cerebral PalsyCompletedNCT01815814
40Spinal Cord Injury: Endurance, Strength and Cardiac Function Induced by Efficient Training ProtocolsCompletedNCT00987155Phase 0
41Assessment of Patients With Multiple Sclerosis (MS)CompletedNCT00001156
42Valor II: The Valiant Thoracic Stent Graft System Clinical StudyCompletedNCT00413231
43Study of an Implantable Functional Neuromuscular Stimulation System for Patients With Spinal Cord InjuriesCompletedNCT00004445
44Intrathecal Morphine on Transcranial Electric Motor-Evoked PotentialsCompletedNCT00596609
45Walking Adaptability Post-Spinal Cord InjuryCompletedNCT01851629
46Evaluation of a Hybrid Prototype Strategy (Electrostimulation of Lower Limb Muscles Associated With Voluntary Strengthening of the Upper Limbs) in Reconditioning to Effort in Patients With Chronic Paraplegia.RecruitingNCT02042508
47Freehand Ultrasound to Evaluate Scapular Kinematics in People With ParaplegiaRecruitingNCT02357914
48Reciprocating Gait Orthoses for Paraplegia PatientsRecruitingNCT02227407
49Adjusting Wheelchair Set-Up to Minimize Shoulder Joint Forces During PropulsionRecruitingNCT00785278
50A Neuroprosthesis for Prolonged Standing After SCI Using Multi-Contact Peripheral Nerve ElectrodesRecruitingNCT01923662

Search NIH Clinical Center for Paraplegia


Cochrane evidence based reviews: paraplegia

Genetic Tests for Paraplegia

About this section

Anatomical Context for Paraplegia

About this section

MalaCards organs/tissues related to Paraplegia:

33
Spinal cord, Bone, Breast, T cells, Lung, Endothelial, Testes

Animal Models for Paraplegia or affiliated genes

About this section

MGI Mouse Phenotypes related to Paraplegia:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00036316.4FA2H, HSPD1, KIF5A, L1CAM, PLP1, PNPLA6
2MP:00053865.6ATL1, CYP7B1, FA2H, HSPD1, KIF5A, L1CAM

Publications for Paraplegia

About this section

Articles related to Paraplegia:

(show top 50)    (show all 1131)
idTitleAuthorsYear
1
Correlation between Serum Osteopontin and miR-181a Levels in Allergic Rhinitis Children. (27199509)
2016
2
Increased Lipocalin 2 level may have important role in thrombotic events in patients with polycythemia vera and essential thrombocythemia. (27161323)
2016
3
Importance of Neurogenic Bladder as a Cause of Drainage Failure. (27006442)
2016
4
Relationship of postcontrast myocardial T1 value and delayed enhancement to reduced cardiac function and serious arrhythmia in dilated cardiomyopathy with left ventricular ejection fraction less than 35. (25900838)
2015
5
An Unusual Bone Metastasis Mimicking SAPHO (Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis) Syndrome on Bone Scintigraphy. (26505860)
2015
6
Unexpected cause of superior vena cava syndrome. (26312222)
2015
7
Exome sequencing reveals mutations in MFN2 and GDAP1 in severe Charcot-Marie-Tooth disease. (25403865)
2014
8
Acute myocardial infarction in Kabuki syndrome: chance occurrence or a novel risk factor for premature atherosclerosis? (25065336)
2014
9
A meta-analysis of the association between the hOGG1 Ser326Cys polymorphism and the risk of esophageal squamous cell carcinoma. (23762419)
2013
10
Modeling the binding mechanism of Alzheimer's AI^1-42 to nicotinic acetylcholine receptors based on similarity with snake I+-neurotoxins. (23022323)
2013
11
Surgical treatment of 32 cases of long-term atopic keratoconjunctivitis using the amniotic membrane. (23949491)
2013
12
Studies of microparticles in patients with the antiphospholipid syndrome (APS). (22635239)
2012
13
Birth outcome in women with breast cancer, cutaneous malignant melanoma, or Hodgkin's disease: a review. (21326655)
2011
14
Galectin-3 expression: a useful tool in the differential diagnosis of posterior fossa tumors in children. (20711594)
2011
15
Regulation of B cell activating factor (BAFF) receptor expression by NF-I9B signaling in rheumatoid arthritis B cells. (21515993)
2011
16
Corneal biomechanical properties and intraocular pressure in high myopic anisometropia. (20531203)
2010
17
Repair of extensive perineal hypospadias in a Boston terrier using tubularized incised plate urethroplasty. (19949553)
2009
18
Mammalian metallopeptidase inhibition at the defense barrier of Ascaris parasite. (19179285)
2009
19
Numerical analysis of etoposide induced DNA breaks. (19516899)
2009
20
The human neonatal B cell response to respiratory syncytial virus uses a biased antibody variable gene repertoire that lacks somatic mutations. (19804909)
2009
21
HLA-B27 homozygosity has no influence on clinical manifestations and functional disability in ankylosing spondylitis. (19772787)
2009
22
Detection and characterization of proteinase K-sensitive disease-related prion protein with thermolysin. (18684106)
2008
23
Quantitation of the JAK2V617F mutation in microdissected bone marrow trephines: equal mutational load in myeloid lineages and rare involvement of lymphoid cells. (18551750)
2008
24
Suppression of U937 human monocytic leukemia cell growth by dideoxypetrosynol A, a polyacetylene from the sponge Petrosia sp., via induction of Cdk inhibitor p16 and down-regulation of pRB phosphorylation. (16786142)
2006
25
Dengue fever with papilledema: a case of dengue-3 virus infection in central nervous system. (16797229)
2006
26
Epigenome analyses using BAC microarrays identify evolutionary conservation of tissue-specific methylation of SHANK3. (15895082)
2005
27
Analysis of biallelic inactivation of the von Hippel-Lindau tumor suppressor gene VHL in patients of renal cell carcinoma patient]. (15771820)
2005
28
Block of human NaV1.5 sodium channels by novel alpha-hydroxyphenylamide analogues of phenytoin. (15066664)
2004
29
Same gain, less pain: potential patient preferences for adjuvant treatment in premenopausal women with early breast cancer. (15519512)
2004
30
Cutting edge: induction of the antigen-processing enzyme IFN-gamma-inducible lysosomal thiol reductase in melanoma cells Is STAT1-dependent but CIITA-independent. (15240658)
2004
31
Efficacy and safety of tamsulosin in the treatment of urological diseases. (14680444)
2004
32
SHORT syndrome. (12514365)
2003
33
Characterization of mac25/angiomodulin expression by high endothelial venule cells in lymphoid tissues and its identification as an inducible marker for activated endothelial cells. (12407018)
2002
34
Lysosomal proteases as potential targets for the induction of apoptotic cell death in human neuroblastomas. (11857353)
2002
35
Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. (11157491)
2001
36
The ATPase cycle of Hsp90 drives a molecular 'clamp' via transient dimerization of the N-terminal domains. (10944121)
2000
37
Infantile hypertrophic pyloric stenosis in a 5-month-old baby: case report. (10974761)
2000
38
Multicenter study of paroxysmal dyskinesias in Japan--clinical and pedigree analysis. (10435504)
1999
39
Expression and cytogenetic localization of the human SM22 gene (TAGLN). (9615232)
1998
40
Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Etude Cas TAcmoins sur 'Infarctus du Myocarde. (8728314)
1996
41
Endothelial cell-induced resistance to cyclosporin A in human peripheral blood T cells requires contact-dependent interactions involving CD2 but not CD28. (7523510)
1994
42
Gamma-hydroxybutyrate: an overview of the pros and cons for it being a neurotransmitter and/or a useful therapeutic agent. (7914688)
1994
43
Antenatal diagnosis and outcome in hydrops fetalis. (8487153)
1993
44
The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. (1389951)
1992
45
Public health aspects of opisthorchiasis in Thailand. (6542380)
1984
46
Plasmapheresis treatment of idiopathic rapidly progressive glomerulonephritis. (6642730)
1983
47
Electromyographic and esophagomanometric findings in clinically normal dogs and in dogs with idiopathic megaesophagus. (447549)
1979
48
Hypersplenism. (14863408)
1951
49
50

Variations for Paraplegia

About this section

Expression for genes affiliated with Paraplegia

About this section
Search GEO for disease gene expression data for Paraplegia.

Pathways for genes affiliated with Paraplegia

About this section

Pathways related to Paraplegia according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
18.9KIAA0196, KIF5A, SPG20, SPG21, ZFYVE27

GO Terms for genes affiliated with Paraplegia

About this section

Cellular components related to Paraplegia according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1midbodyGO:003049610.1SPAST, SPG20
2early endosomeGO:00057699.8HSPD1, KIAA0196, NIPA1
3endoplasmic reticulum membraneGO:00057899.4ATL1, RTN2, ZFYVE27

Biological processes related to Paraplegia according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1anterograde axonal transportGO:000808910.1SPAST, SPG7

Sources for Paraplegia

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet